[go: up one dir, main page]

MX2012009079A - Formulaciones de rasagilina de liberación prolongada y usos de las mismas. - Google Patents

Formulaciones de rasagilina de liberación prolongada y usos de las mismas.

Info

Publication number
MX2012009079A
MX2012009079A MX2012009079A MX2012009079A MX2012009079A MX 2012009079 A MX2012009079 A MX 2012009079A MX 2012009079 A MX2012009079 A MX 2012009079A MX 2012009079 A MX2012009079 A MX 2012009079A MX 2012009079 A MX2012009079 A MX 2012009079A
Authority
MX
Mexico
Prior art keywords
rasagiline
extended release
release formulations
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
MX2012009079A
Other languages
English (en)
Other versions
MX354423B (es
Inventor
Yoram Sela
Itschak Lamensdorf
Nurit Livnah
Tomer Madmon
Original Assignee
Pharma Two B Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43896855&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012009079(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharma Two B Ltd filed Critical Pharma Two B Ltd
Publication of MX2012009079A publication Critical patent/MX2012009079A/es
Publication of MX354423B publication Critical patent/MX354423B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención proporciona varias composiciones farmacéuticas, en particular para la administración oral, formuladas para la liberación prolongada de compuestos activos útiles en el tratamiento de enfermedades neurodegenerativas, en particular la enfermedad de Parkinson, y lesiones del sistema nervioso; el compuesto activo comprendido dentro de estas composiciones de preferencia se selecciona de N-propargil-1-aminoindano, un enantiómero del mismo, o una sal farmacéuticamente aceptable del mismo, más preferiblemente rasagilina o una sal farmacéuticamente aceptable de la misma.
MX2012009079A 2010-02-03 2011-02-03 Formulaciones de rasagilina de liberación prolongada y usos de las mismas. MX354423B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30101910P 2010-02-03 2010-02-03
PCT/IL2011/000126 WO2011095973A1 (en) 2010-02-03 2011-02-03 Extended release formulations of rasagiline and uses thereof

Publications (2)

Publication Number Publication Date
MX2012009079A true MX2012009079A (es) 2012-12-17
MX354423B MX354423B (es) 2018-03-02

Family

ID=43896855

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012009079A MX354423B (es) 2010-02-03 2011-02-03 Formulaciones de rasagilina de liberación prolongada y usos de las mismas.

Country Status (25)

Country Link
US (1) US9943489B2 (es)
EP (2) EP2531181B1 (es)
JP (3) JP6045347B2 (es)
KR (1) KR101791715B1 (es)
CN (1) CN102791258B (es)
AU (1) AU2011212068B2 (es)
BR (1) BR112012019374B1 (es)
CA (1) CA2789006C (es)
CL (1) CL2012002175A1 (es)
CY (1) CY1121781T1 (es)
DK (1) DK2531181T3 (es)
ES (1) ES2733133T3 (es)
HU (1) HUE044221T2 (es)
IL (1) IL221274A (es)
LT (1) LT2531181T (es)
MX (1) MX354423B (es)
NZ (1) NZ602111A (es)
PL (1) PL2531181T3 (es)
PT (1) PT2531181T (es)
RS (1) RS58988B1 (es)
RU (2) RU2607595C2 (es)
SG (1) SG183150A1 (es)
TR (1) TR201909277T4 (es)
WO (1) WO2011095973A1 (es)
ZA (1) ZA201206462B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2607595C2 (ru) * 2010-02-03 2017-01-10 Фарма Ту Б Лтд. Составы разагилина с пролонгированным высвобождением и их применение
CA2758556A1 (en) * 2011-11-17 2013-05-17 Pharmascience Inc. Pharmaceutical composition of amphetamine mixed salts
KR102276896B1 (ko) * 2012-01-12 2021-07-14 파마 투 비 엘티디 파킨슨병의 고정용량 조합 치료법
US9504657B2 (en) * 2012-01-12 2016-11-29 Pharmatwob Ltd. Fixed dose combination therapy of Parkinson's disease
WO2013139292A1 (zh) 2012-03-23 2013-09-26 中国人民解放军军事医学科学院毒物药物研究所 一种含辛弗林和托吡酯的联合产品
CN102579367B (zh) * 2012-03-23 2014-03-12 中国人民解放军军事医学科学院毒物药物研究所 托吡酯缓释药物组合物、其制备方法及用途
CN103316026B (zh) 2012-03-23 2016-05-11 中国人民解放军军事医学科学院毒物药物研究所 含芬特明和托吡酯的联合产品及其制备方法
WO2014028868A1 (en) * 2012-08-17 2014-02-20 Teva Pharmaceutical Industries Ltd. Parenteral formulation of rasagiline
WO2014192022A1 (en) * 2013-05-20 2014-12-04 Cadila Healthcare Limited Pharmaceutical compositions of rasagiline
US20150275167A1 (en) * 2014-03-28 2015-10-01 Corning Incorporated Composition and method for cell culture sustained release
CA2961097C (en) 2014-09-15 2023-09-26 Orphazyme Aps Extended-release pharmaceutical formulation comprising arimoclomol
CA3064006C (en) 2017-05-19 2025-09-16 Biscayne Neurotherapeutics, Inc. Modified-Release Pharmaceutical Compositions of Huperzine and Their Methods of Use
CN107049985B (zh) * 2017-06-07 2020-06-19 广州帝奇医药技术有限公司 一种抗帕金森病药物的长效缓释制剂及其制备方法
AU2019261406A1 (en) * 2018-04-25 2020-12-17 Neurocentria, Inc. Magnesium threonate compositions and uses thereof
EP4541419A3 (en) 2018-11-19 2025-05-07 Supernus Pharmaceuticals, Inc. Use of higher doses of modified release huperzine formulations
CN114126408A (zh) * 2019-05-31 2022-03-01 戴纳立制药公司 嘧啶基氨基-吡唑化合物的改良释放配制品和治疗方法
KR20210014289A (ko) 2019-07-30 2021-02-09 (주)비씨월드제약 라사길린을 함유하는 서방출성 미립구의 제조방법
AR121619A1 (es) * 2020-03-25 2022-06-22 Inibsa Ginecologia S A Una forma de dosificación oral de múltiples unidades de liberación modificada de succinato de doxilamina y clorhidrato de piridoxina y un procedimiento para su preparación
ES3037587T3 (en) * 2021-05-11 2025-10-03 Advicenne Prolonged-release pharmaceutical composition for oral administration of sultiame
CN118680910B (zh) * 2024-08-26 2024-12-03 山东齐都药业有限公司 用于缓释递送雷沙吉兰甲磺酸盐的药物组合物及其制备方法和应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4415547A (en) * 1982-06-14 1983-11-15 Sterling Drug Inc. Sustained-release pharmaceutical tablet and process for preparation thereof
US4861800A (en) 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
HU208484B (en) 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
CA2039194C (en) 1990-08-31 1997-01-28 Norton W. Milgram Uses of l-deprenyl and compositions for same
US5225446A (en) 1990-08-31 1993-07-06 Deprenyl Animal Health, Inc. Use of 1-deprenyl for retention of specific physiological functions
US5151449A (en) 1990-08-31 1992-09-29 Deprenyl Animal Health, Inc. Use of L-deprenyl for retention of specific physiological functions
US5192808A (en) 1990-08-31 1993-03-09 Deprenyl Animal Health, Inc. Therapeutic effect of L-deprenyl in the management of pituitary-dependent hyperadrenocorticism (cushing's disease)
US5169868A (en) 1991-03-01 1992-12-08 University Of Saskatchewan Aliphatic propargylamines as specific mao-b inhibitors
AU1450592A (en) 1991-04-04 1992-11-02 University Of Toronto Innovations Foundation, The Use of deprenyl to maintain, prevent loss, or recover nerve cell function
WO1992021333A2 (en) 1991-05-24 1992-12-10 Pharmavene, Inc. Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors
IL99759A (en) 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
US5242950A (en) 1992-04-23 1993-09-07 Somerset Pharmaceuticals, Inc. Treatment of macular degeneration
JP2916978B2 (ja) * 1993-08-25 1999-07-05 エスエス製薬株式会社 放出開始制御型製剤
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
US6348208B1 (en) 1995-01-13 2002-02-19 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
US6251938B1 (en) 1996-12-18 2001-06-26 Teva Pharmaceutical Industries, Ltd., Phenylethylamine derivatives
WO1998027055A1 (en) 1996-12-18 1998-06-25 Teva Pharmaceutical Industries, Ltd. Aminoindan derivatives
US5840979A (en) 1997-07-14 1998-11-24 University Of Saskatchewan Aliphatic propargylamines as cellular rescue agents
CZ20013786A3 (cs) 1999-04-29 2002-02-13 Merck Patent Gmbh Inhibitory glycinového ątěpicího systému jako moľná antipsychotika
WO2003011255A1 (en) * 2001-07-04 2003-02-13 Sun Pharmaceutical Industries Limited Gastric retention controlled drug delivery system
US20040076668A1 (en) 2002-07-03 2004-04-22 Pfizer Inc. Controlled-release pharmaceutical formulations
US7396860B2 (en) * 2002-11-15 2008-07-08 Teva Pharmaceutical Industries, Ltd. Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis
CA2554959A1 (en) * 2004-01-29 2005-08-11 Neuromolecular, Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
EP1778196A4 (en) * 2004-07-26 2008-12-17 Teva Pharma PHARMACEUTICAL DOSAGES CONTAINING RASAGILINE
RS20070512A (sr) * 2005-06-29 2009-01-22 Panacea Biotec Ltd., Farmaceutske kompozicije sa zadržanim otpuštanjem i postupci za njihovo dobijanje
US20070048371A1 (en) * 2005-07-28 2007-03-01 Shojaei Amir H Pharmaceutical formulations/composition of guanfacine suitable for single dose form administration daily
JP2009502957A (ja) * 2005-07-28 2009-01-29 スパーナス ファーマシューティカルズ インコーポレイテッド 機械的特性の向上した徐放性錠剤配合物
CN101032474B (zh) * 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
CN101486655A (zh) * 2008-01-17 2009-07-22 美德（江西）生物科技有限公司 甲磺酸雷沙吉兰晶形及其制备方法
CA2726833C (en) 2008-06-06 2016-03-22 Pharma Two B Ltd. Pharmaceutical compositions for treatment of parkinson's disease
JP2011524353A (ja) 2008-06-10 2011-09-01 テバ ファーマシューティカル インダストリーズ リミティド ラサギリン軟ゼラチンカプセル
US20100041920A1 (en) * 2008-07-18 2010-02-18 Stephen Benedict David Winter New salt forms of an aminoindan derivative
EP2218444A3 (en) 2009-01-23 2010-08-25 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
RU2607595C2 (ru) * 2010-02-03 2017-01-10 Фарма Ту Б Лтд. Составы разагилина с пролонгированным высвобождением и их применение

Also Published As

Publication number Publication date
AU2011212068A1 (en) 2012-09-20
DK2531181T3 (da) 2019-07-15
PT2531181T (pt) 2019-07-17
JP2019048855A (ja) 2019-03-28
RS58988B1 (sr) 2019-08-30
AU2011212068B2 (en) 2016-08-18
KR101791715B1 (ko) 2017-10-30
IL221274A (en) 2017-05-29
US20120301542A1 (en) 2012-11-29
RU2734632C2 (ru) 2020-10-21
RU2607595C2 (ru) 2017-01-10
CA2789006C (en) 2018-11-27
EP3517103A1 (en) 2019-07-31
CA2789006A1 (en) 2011-08-11
RU2016141314A (ru) 2018-12-14
JP6770564B2 (ja) 2020-10-14
HUE044221T2 (hu) 2019-10-28
PL2531181T3 (pl) 2019-09-30
LT2531181T (lt) 2019-07-10
WO2011095973A1 (en) 2011-08-11
MX354423B (es) 2018-03-02
EP2531181A1 (en) 2012-12-12
RU2016141314A3 (es) 2019-12-20
ZA201206462B (en) 2014-02-26
RU2012136723A (ru) 2014-03-10
CN102791258B (zh) 2018-05-08
ES2733133T3 (es) 2019-11-27
KR20120130292A (ko) 2012-11-30
BR112012019374B1 (pt) 2022-01-11
BR112012019374A2 (pt) 2016-05-03
EP2531181B1 (en) 2019-04-10
TR201909277T4 (tr) 2019-07-22
JP6440662B2 (ja) 2018-12-19
CY1121781T1 (el) 2020-07-31
US9943489B2 (en) 2018-04-17
JP6045347B2 (ja) 2016-12-14
CL2012002175A1 (es) 2013-01-11
SG183150A1 (en) 2012-09-27
NZ602111A (en) 2014-10-31
JP2017031189A (ja) 2017-02-09
CN102791258A (zh) 2012-11-21
JP2013518870A (ja) 2013-05-23
IL221274A0 (en) 2012-10-31

Similar Documents

Publication Publication Date Title
MX2012009079A (es) Formulaciones de rasagilina de liberación prolongada y usos de las mismas.
TN2012000421A1 (en) Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
MY165149A (en) Use of binders for manufacturing storage stable formulations
NZ605469A (en) Nalbuphine-based formulations and uses thereof
CA3094580C (en) Oral formulations of cytidine analogs and methods of use thereof
WO2014205229A8 (en) Use of high dose pridopidine for treating huntington's disease
WO2008154083A3 (en) Compounds, compositions and methods for the treatment of synucleinopathies
MY156288A (en) Pharmaceutical formulations containing dopamine receptor ligands.
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
MX2015001917A (es) Composiciones farmaceuticas de memantina.
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
PH12014500065A1 (en) A new therapeutical composition containing apomorphine as active ingredient
MX2009008084A (es) Derivados de 5,6,7,8-tetrahidropteridina como inhibidores de hsp90.
EA201171087A1 (ru) СПОСОБЫ ВВЕДЕНИЯ (4aR,10aR)-1-н-ПРОПИЛ-1,2,3,4,4a,5,10,10a-ОКТАГИДРОБЕНЗО[g]ХИНОЛИН-6,7-ДИОЛА И РОДСТВЕННЫХ СОЕДИНЕНИЙ ЧЕРЕЗ СЛИЗИСТУЮ ОБОЛОЧКУ ПОЛОСТИ РТА, СЛИЗИСТУЮ ОБОЛОЧКУ НОСА ИЛИ КОЖУ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis
MY157673A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
PH12015500823A1 (en) Modified release formulations for oprozomib
MX2012008509A (es) Agente terapeutico o profilactic para enfermedades del tracto biliar.
MX2008011020A (es) Compuestos de receptor sigma.
WO2009148290A3 (en) 3-substituted propanamine compounds
PH12014501051A1 (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
MA32719B1 (fr) Formulations galeniques de composes organiques
MX2014011843A (es) Compuestos para usarse en el tratamiento de neuroblastoma, sarcoma de ewing o rabdomiosarcoma.
MX2008011017A (es) Compuestos de receptor sigma.
UA101370C2 (ru) Пероральные составы, которые содержат аналоги цитидина, и способы их использования

Legal Events

Date Code Title Description
FG Grant or registration